Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 16, 2011
Thyroid stiffness assessment by acoustic radiation force impulse elastography (ARFI)I Sporea, M Vlad, S Bota, et al.
Revue Des Maladies Respiratoires|March 24, 2012
[Clomipramine hypersensitivity with predominantly pulmonary involvement]J Gallego, P-A Hauss, M Salaün, et al.
The European Respiratory Journal|March 1, 2003
Occupational and nonoccupational factors associated with high grade bronchial pre-invasive lesionsC Paris, J Benichou, S Bota, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)F Barlesi, R Gervais, H Lena, et al.
The European Respiratory Journal|March 2, 2006
Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximabS Jaffre, F Jardin, S Dominique, et al.
British Journal of Cancer|September 22, 2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)H LeCaer, F Barlesi, R Corre, et al.
Journal of Biomedical Materials Research. Part A|August 21, 2010
Biomaterial topography alters healing in vivo and monocyte/macrophage activation in vitroPaige C S Bota, Angela M B Collie, Pauli Puolakkainen, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2007
Double stenting of oesophagus and airways in palliative treatment of patients with oesophageal cancer is efficient but associated with a high morbidityS Lecleire, M Antonietti, F Di Fiore, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2014
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyJ B Auliac, C Chouaid, L Greillier, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
Pageof 3